Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases
Role of CD3+ and NKp46+ Cells in Resected Colorectal Liver Metastases.
1 other identifier
observational
121
1 country
1
Brief Summary
The long-term outcome of patients resected for colorectal liver metastases (CLM) after neoadjuvant chemotherapy (CHT) depends by several tumoral and non-tumoral factors, such as the immune response to the tumor and to the CHT. The aim of this study was to investigate the impact of the pathological and immunological response in patients undergoing liver resection for CLM after CHT in regards to the long-term outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2013
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2015
CompletedFirst Submitted
Initial submission to the registry
November 18, 2015
CompletedFirst Posted
Study publicly available on registry
November 26, 2015
CompletedNovember 26, 2015
November 1, 2015
2.6 years
November 18, 2015
November 24, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival
5 years
Interventions
Removal of a part of the liver during surgery
Eligibility Criteria
Patients with colorectal liver metastases scheduled for surgery at our Unit.
You may qualify if:
- histological proven colorectal liver metastases
- complete clinical, surgical, pathological and follow-up data
You may not qualify if:
- non-radical surgery
- incomplete clinical, surgical, pathological and follow-up data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Hepatobiliary and General Surgery, Humanitas Research Hospital, University of Milan
Rozzano, Milan, 20089, Italy
Related Publications (2)
Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, Lugli E, Torzilli G, Gershwin ME, Mavilio D. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun. 2016 Jan;66:40-50. doi: 10.1016/j.jaut.2015.08.011. Epub 2015 Aug 30.
PMID: 26330348RESULTHudspeth K, Pontarini E, Tentorio P, Cimino M, Donadon M, Torzilli G, Lugli E, Della Bella S, Gershwin ME, Mavilio D. The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun. 2013 Oct;46:55-65. doi: 10.1016/j.jaut.2013.07.003. Epub 2013 Jul 21.
PMID: 23880068RESULT
Biospecimen
We use the surgical specimens.
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Guido Torzilli, MD, PhD
Humanitas University, Humanitas Research Hospital IRCCS
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Surgery
Study Record Dates
First Submitted
November 18, 2015
First Posted
November 26, 2015
Study Start
January 1, 2013
Primary Completion
August 1, 2015
Study Completion
August 1, 2015
Last Updated
November 26, 2015
Record last verified: 2015-11